Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Leen Sas"'
Autor:
Leen, Sas1,2 leen.sas@uantwerpen.be, Steven, Van Laere1,3, Marie, Dierick Anne4, Valérie, Duwel4, Annemie, De Pauw5, Eynden Gert, Van Den1, Peter, Van Dam2, Luc, Dirix1, Peter, Vermeulen1, Filip, Lardon2
Publikováno v:
Pathology Research International. 2014, p1-8. 8p.
Publikováno v:
Breast Cancer Management. 3:53-61
SUMMARY Inflammatory breast cancer (IBC) is a very aggressive form of breast cancer with a high mortality rate. Most patients have lymph node metastasis at the time of diagnosis and 30% of patients already have metastases in distant organs. IBC is no
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1864c091315d275b6cab1cbd9e1b0d31
https://doi.org/10.2217/bmt.13.72
https://doi.org/10.2217/bmt.13.72
Publikováno v:
Cancer Research. 73:P5-09
Introduction:Endocrine treatment is the mainstay of therapy for patients with Estrogen Receptor positive (ER+) breast cancer.Unfortunately, primary and secondary resistance to endocrine therapy are a major clinical problem. Previous studies have sugg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::affab13689b6a50187648f56053bc122
https://doi.org/10.1158/0008-5472.sabcs13-p5-09-04
https://doi.org/10.1158/0008-5472.sabcs13-p5-09-04
Autor:
Leen Sas, Steven Van Laere, Peter B. Vermeulen, Els M.J.J. Berns, Maurice P.H.M. Jansen, Caroline Van Cauwenberghe, John A. Foekens, Kirsten Ruigrok-Ritstier, Peter van Dam, Carolien H.M. van Deurzen, Anieta M. Sieuwerts, John W.M. Martens, Mieke M. Timmermans, Pascal Finetti, Sabine C. Linn, Marleen Kok, Filip Lardon, Diana Ramirez-Ardila, Paul Roepman, François Bertucci, Iris Simon, Luc Dirix, Maxime P. Look
Publikováno v:
Molecular Oncology, 9(6), 1218. Elsevier
Molecular Oncology
Molecular Oncology, 2015, 9 (6), pp.1218-1233. ⟨10.1016/j.molonc.2015.02.006⟩
Molecular Oncology, 9(6), 1218-1233. John Wiley & Sons Ltd.
Molecular Oncology
Molecular Oncology, 2015, 9 (6), pp.1218-1233. ⟨10.1016/j.molonc.2015.02.006⟩
Molecular Oncology, 9(6), 1218-1233. John Wiley & Sons Ltd.
Background: Patients with Estrogen Receptor alpha-positive (ER+) Inflammatory Breast Cancer (IBC) are less responsive to endocrine therapy compared with ER+ non-IBC (nIBC) patients. The study of ER+ IBC samples might reveal biomarkers for endocrine r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4938706085c2b0e94df466f24f21813b
https://dspace.library.uu.nl/handle/1874/333818
https://dspace.library.uu.nl/handle/1874/333818
Autor:
Jan Hauspy, Peter B. Vermeulen, Filip Lardon, Steven Van Laere, Leen Sas, Patrick Pauwels, Luc Dirix, Peter van Dam
Publikováno v:
Breast cancer research
Breast Cancer Research : BCR
Breast Cancer Research : BCR
Endocrine therapy is a commonly used treatment for estrogen receptor (ER)-positive breast cancer. Although endocrine therapy has a favorable outcome in many patients, development of resistance is common. Recent studies have shown that NFκB, a transc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7a973b0029a7eeb9b35e1f676f1cccf
https://doi.org/10.1186/bcr3196
https://doi.org/10.1186/bcr3196
Autor:
P. De Mesmaeker, A. Wojtasik, Leen Sas, S. Van Laere, Xuan Bich Trinh, M. Rasschaert, A Prové, P A van Dam, H. van de Velde, Luc Y. Dirix, I. Deleu, P. Vinken, Wiebren A.A. Tjalma, Peter Vermeulen
Publikováno v:
Oncology Reports.
The majority of patients with hormone receptor-positive metastatic breast cancer die from disease progression despite different types of anti-hormonal treatments. Preclinical studies have indicated that resistance to anti-hormonal therapies may be th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::210aae6ad76b79d9a4ee0222a9c82012
https://doi.org/10.3892/or.2011.1562
https://doi.org/10.3892/or.2011.1562
Publikováno v:
Cancer Research. 73:99-99
Introduction: Breast cancer is a heterogeneous disease exemplified by patients with Estrogen Receptor (ER) positive and negative breast cancer. Treatment of patients with breast cancer is increasingly governed by this notion of heterogeneity. For exa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e86e995f4aa68596c8d3ed9d3e7eb7a8
https://doi.org/10.1158/1538-7445.am2013-99
https://doi.org/10.1158/1538-7445.am2013-99
Autor:
Eleni van Schooneveld, Steven S. Van Laere, Peter B. Vermeulen, Melike Marsan, Peter van Dam, Dieter Peeters, Luc Dirix, Leen Sas, Filip Lardon
Publikováno v:
Cancer Research. 72:3919-3919
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Background: Patients with estrogen receptor (ER)-positive breast cancers are generally treated with endocrine therapy, but in a considerable fraction of patients resi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::60350ff9c79abc01b7e3addbe009bd51
https://doi.org/10.1158/1538-7445.am2012-3919
https://doi.org/10.1158/1538-7445.am2012-3919
Autor:
Steven Van Laere, Van Den Eynden G. Gert, Peter B. Vermeulen, Leen Sas, Luc Dirix, Dieter Peeters, Wiebren A.A. Tjalma, Peter A. van Dam, Xuan Bich Trinh
Publikováno v:
Cancer Research. 71:3203-3203
INTRODUCTION AND OBJECTIVES: Ovarian cancer is the leading cause of mortality among gynecological cancers. Identification of relevant pathways may contribute in individualization of treatment strategies. The objective of this study was to relate cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d8382c4dbefdd47088e0e38eb7f001d3
https://doi.org/10.1158/1538-7445.am2011-3203
https://doi.org/10.1158/1538-7445.am2011-3203